Stephan Bernstein, CEO of GreenRoc, details the PFS results for the new graphite processing plant. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDNL.L Regulatory News (DNL)

  • There is currently no data for DNL

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Grant of Deferred Share Awards

2 Aug 2021 07:00

RNS Number : 1584H
Diurnal Group PLC
02 August 2021
 

2 August 2021

 

Diurnal Group plc

("Diurnal" or the "Company")

 

Grant of Deferred Share Awards

 

Diurnal Group plc (AIM: DNL), the specialty pharmaceutical company targeting patient needs in chronic endocrine (hormonal) diseases, announces the following deferred bonus share awards over ordinary shares of 5 pence ("Ordinary Shares") in Diurnal were granted under the Diurnal Group plc Long Term Incentive Plan (the "Plan") to persons discharging managerial responsibilities ("PDMR") in respect of the bonus due for the financial year ended 30 June 2021:

 

PDMR

Total number of shares under award

Type of award

Martin Whitaker

157,500

Deferred bonus share

Richard Bungay

84,000

Deferred bonus share

Richard Ross

26,892

Deferred bonus share

 

Under the rules of the Plan, up to 50% of the annual bonus payable to the senior management team are settled in deferred share bonus awards. Annual bonuses are payable at the sole discretion of the Remuneration Committee on the basis set out in the 2020 annual report. The bonus performance criteria for 2020/2021 were as follows:

 

Objective

Weighting

Performance assessed

% of bonus awarded

Obtain approval for Chronocort® in congenital adrenal hyperplasia in the EU

25%

80%

20%

Exceed forecast revenues by 20%

25%

0%

0%

Complete supply chain enhancements for Alkindi® and Chronocort® to meet future capacity requirements and reduce cost of sales

25%

40%

10%

Complete DITEST™ preparatory work and submit IND application to the US FDA

25%

80%

20%

TOTAL

100%

50%

 

The deferred bonus share awards will ordinarily vest on the first anniversary of their grant, subject to the grantee's continued service. The awards were granted under award agreements that incorporated the terms of the Plan. No consideration is due to be payable on vesting.

 

For further information, please visit www.diurnal.co.uk or contact:

Diurnal Group plc

+44 (0)20 3727 1000

Martin Whitaker, Chief Executive Officer

Richard Bungay, Chief Financial Officer

Panmure Gordon (UK) Limited (Nominated Adviser and Sole Broker)

+44 (0)20 7886 2500

Corporate Finance: Freddy Crossley, Emma Earl

Corporate Broking: Rupert Dearden

FTI Consulting (Media and Investor Relations)

+44 (0)20 3727 1000

Simon Conway

Victoria Foster Mitchell

Alex Davis

Notes to Editors

 

About Diurnal Group plc

Diurnal Group plc is a European, UK-headquartered, specialty pharmaceutical company dedicated to developing hormone therapeutics to aid lifelong treatment for rare and chronic endocrine conditions, including congenital adrenal hyperplasia, adrenal insufficiency, hypogonadism and hypothyroidism. Its expertise and innovative research activities focus on circadian-based endocrinology to yield novel product candidates in the rare and chronic endocrine disease arena.

 

For further information about Diurnal, please visit www.diurnal.co.uk

 

Details of the full notifications received by the Company are set out below:

 

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

 

Martin Whitaker

2

 

Reason for the notification

 

a)

 

Position/status

 

Chief Executive Officer

b)

 

Initial notification /Amendment

 

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

Diurnal Group plc

b)

 

LEI

 

213800I2HNUNZN1LDH29

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

a)

 

Description of the financial instrument, type of instrument

Ordinary Shares of 5 pence each in Diurnal Group plc

Identification code

GB00BDB6Q760

b)

 

Nature of the transaction

 

Grant of nil cost awards under the Diurnal Group plc Long Term Incentive Plan as follows:

 

Deferred bonus award over 157,500 ordinary shares.

 

The deferred bonus award will ordinarily vest on the first anniversary of their grant subject to continued service.

 

c)

 

Price(s) and volume(s)

Price(s)

Volume(s)

£nil

157,500

d)

 

Aggregated information

- Aggregated volume

157,500

- Price

£nil

e)

 

Date of the transaction

 

2 August 2021

f)

 

Place of the transaction

 

Outside a trading venue

 

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

 

 Richard Bungay

2

 

Reason for the notification

 

a)

 

Position/status

 

Chief Financial Officer

b)

 

Initial notification /Amendment

 

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

Diurnal Group plc

b)

 

LEI

 

213800I2HNUNZN1LDH29

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

a)

 

Description of the financial instrument, type of instrument

Ordinary Shares of 5 pence each in Diurnal Group plc

Identification code

GB00BDB6Q760

b)

 

Nature of the transaction

 

Grant of nil cost awards under the Diurnal Group plc Long Term Incentive Plan as par value options as follows:

 

Deferred bonus award over 84,000 ordinary shares.

 

The deferred bonus award will ordinarily vest on the first anniversary of their grant subject to continued service.

 

c)

 

Price(s) and volume(s)

Price(s)

Volume(s)

£nil

84,000

d)

 

Aggregated information

- Aggregated volume

84,000

- Price

£nil

e)

 

Date of the transaction

 

2 August 2021

f)

 

Place of the transaction

 

Outside a trading venue

 

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

 

 Richard Ross

2

 

Reason for the notification

 

a)

 

Position/status

 

Chief Scientific Officer

b)

 

Initial notification /Amendment

 

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

Diurnal Group plc

b)

 

LEI

 

213800I2HNUNZN1LDH29

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

a)

 

Description of the financial instrument, type of instrument

Ordinary Shares of 5 pence each in Diurnal Group plc

Identification code

GB00BDB6Q760

b)

 

Nature of the transaction

 

Grant of nil cost awards under the Diurnal Group plc Long Term Incentive Plan as par value options as follows:

 

Deferred bonus award over 26,862 ordinary shares.

 

The deferred bonus award will ordinarily vest on the first anniversary of their grant subject to continued service.

 

 

c)

 

Price(s) and volume(s)

Price(s)

Volume(s)

£nil

26,892

d)

 

Aggregated information

- Aggregated volume

26,892

- Price

£nil

e)

 

Date of the transaction

 

2 August 2021

f)

 

Place of the transaction

 

Outside a trading venue

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHDZGGRNMRGMZM
Date   Source Headline
30th Apr 20193:40 pmRNSHolding(s) in Company
30th Apr 20192:43 pmRNSHolding(s) in Company
26th Apr 20195:52 pmRNSDirector Dealings and Issue of Equity
26th Apr 20193:10 pmRNSHolding(s) in Company
25th Apr 20197:15 amEQSHardman & Co Research: Diurnal Group (DNL): Clarity for Chronocort regulatory pathway
24th Apr 20197:00 amRNSGrant of Orphan Drug Designation in Australia
11th Apr 20197:00 amRNSPositive Scientific Advice from EMA for Chronocort
28th Mar 20197:00 amRNSDiurnal signs marketing and distribution agreement
28th Mar 20197:00 amRNSInterim Results
20th Mar 20197:00 amRNSUpdate on Alkindi US development
25th Feb 20197:00 amRNSSubmission of MAA for Alkindi and Second Patent
11th Feb 201911:00 amRNSNotice of Interim Results
17th Jan 20197:00 amRNSDirector Dealings
16th Jan 20197:15 amEQSHardman & Co Research: Diurnal Group (DNL): Chronocort - seeking regulatory advice
10th Jan 201912:18 pmRNSStatement regarding Price Movement
10th Jan 20197:00 amRNSGrant of second US patent for Chronocort
24th Dec 20187:00 amRNSDirector Dealings and Issue of Equity
12th Dec 20184:02 pmRNSDirector Dealings
11th Dec 20187:00 amRNSRegulatory package for Scientific Advice in Europe
4th Dec 20181:08 pmRNSDirector/PDMR Shareholding
14th Nov 201811:38 amRNSResults of Annual General Meeting
14th Nov 201810:16 amRNSIssue of Equity and Exercise of Options
18th Oct 20187:15 amEQSHardman & Co Research: Diurnal Group (DNL): Unexpected Phase III trial outcome
17th Oct 20187:00 amRNSUpdate on late-stage development pipeline
8th Oct 20184:00 pmRNSPosting of Annual Report and AGM Notice
8th Oct 20182:45 pmRNSSMC Approves The Use of Alkindi
8th Oct 20187:00 amRNSHeadline Data for Chronocort European Phase III
5th Oct 20187:00 amRNSFirst patients enrolled in US Chronocort Phase III
20th Sep 20187:00 amRNSResults for the year ended 30 June 2018
15th Aug 201811:11 amRNSUpdate on Alkindi® in Germany
10th Jul 20181:36 pmRNSDirector/PDMR Shareholding
21st Jun 20187:00 amRNSNotice of Results
18th Jun 20184:54 pmRNSDirector/PDMR Shareholding
18th May 20183:33 pmRNSDirector Dealings
18th May 20181:11 pmRNSAppointment of NOMAD and Joint Broker
15th May 20188:13 amRNSLaunch of Alkindi for paediatric AI in Germany
11th May 20182:41 pmRNSDirector Declaration
17th Apr 20183:58 pmRNSHolding(s) in Company
5th Apr 20182:08 pmRNSDirector/PDMR Shareholding
5th Apr 20188:01 amRNSDirector/PDMR Shareholding
3rd Apr 20182:39 pmRNSResult of GM and Completion of £10.5m Placing
21st Mar 20187:15 amRNSHardman & Co: New capital funds commercial plans
20th Mar 20185:20 pmRNSPlacing Update
14th Mar 20188:47 amRNSProposed Placing
12th Mar 20187:00 amRNSAppointment of CRO to support US Chronocort trials
12th Mar 20187:00 amRNSHalf-year Report
22nd Feb 20187:00 amRNSDiurnal announces grant of first patents in Japan
19th Feb 20187:00 amRNSCommercialisation agreement in Australia and NZ
13th Feb 20187:00 amRNSEuropean marketing authorisation for Alkindi®
12th Feb 20187:00 amRNSCompletion of patient enrolment in EU Phase III

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.